Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation

Pituitary

Volumn 17, Issue 6, 2014, Pages 530-538

  Maclean, Jillian ^a   Aldridge, Matthew ^a   Bomanji, Jamshed ^a   Short, Susan ^a,b   Fersht, Naomi ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Atypical pituitary adenoma; Lutetium; Peptide receptor radionuclide therapy; Pituitary carcinoma

Indexed keywords

DEXAMETHASONE; DOTATATE LU 177; LUTETIUM 177; ONDANSETRON; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 68GA-DOTATATE; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ADULT; ARTICLE; ATYPICAL PITUITARY CARCINOMA; CANCER CONTROL; CANCER RADIOTHERAPY; CASE REPORT; DISEASE ACTIVITY; DOSIMETRY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; EDEMA; GAMMA CAMERA; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; RADIATION RESPONSE; TREATMENT RESPONSE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; METABOLISM; MIDDLE AGED; PITUITARY NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROLACTINOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; LUTETIUM; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROLACTINOMA; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84912047101     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0540-y     Document Type: Article

References (40)

1. Saeger W, Ludecke DK, Buchfelder M et al (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216
2. Zada G, Woodmansee WW, Ramkissoon S et al (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114:336–344
3. Kaltsas GA, Nomikos P, Kontogeorgos G et al (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089–3099
4. Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121
5. Ortiz LD, Syro LV, Scheithauer BW et al (2012) Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 67(Suppl 1):119–123
6. Kaltsas GA, Mukherjee JJ, Plowman PN et al (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83:4233–4238
7. Colao A, Grasso LF, Pivonello R et al (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12:1561–1570
8. Laws ER Jr, Morris AM, Maartens N (2003) Gliadel for pituitary adenomas and craniopharyngiomas. Neurosurgery 53:255–269 discussion 259–260
9. Ortiz LD, Syro LV, Scheithauer BW et al (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15:445–449
10. Ramirez C, Cheng S, Vargas G et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751
11. Acosta-Gomez MJ, Muros MA, Llamas-Elvira JM et al (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78:110–115
12. Jaquet P, Ouafik L, Saveanu A et al (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268–3276
13. Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74
14. Saveanu A, Gunz G, Guillen S et al (2006) Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83:258–263
15. Hofland LJ, Lamberts SW, Feelders RA (2010) Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells. Neuroendocrinology 92(Suppl 1):11–16
16. Hofland LJ, Feelders RA, de Herder WW et al (2010) Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol 326:89–98
17. Fusco A, Giampietro A, Bianchi A et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15:571–578
18. Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29:193–207
19. Kuyumcu S, Ozkan ZG, Sanli Y et al (2013) Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 27:538–545
20. Kunikowska J, Krolicki L, Pawlak D et al (2012) Semiquantitative analysis and characterization of physiological biodistribution of (68)Ga-DOTA-TATE PET/CT. Clin Nucl Med 37:1052–1057
21. Boy C, Heusner TA, Poeppel TD et al (2011) 68 Ga-DOTATOC PET/CT and somatostatin receptor (sst1–sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 38:1224–1236
22. Shastry M, Kayani I, Wild D et al (2010) Distribution pattern of 68 Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1025–1032
23. Veit JA, Boehm B, Luster M et al (2013) Detection of paranasal ectopic adrenocorticotropic hormone-secreting pituitary adenoma by Ga-68-DOTANOC positron-emission tomography-computed tomography. Laryngoscope 123:1132–1135
24. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130
25. van Essen M, Krenning EP, Kooij PP et al (2006) Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47:1599–1606
26. Bartolomei M, Bodei L, De Cicco C et al (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407–1416
27. Baldari S, Ferrau F, Alafaci C et al (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(Suppl 1):S57–S60
28. Komor J, Reubi JC, Christ ER (2013) Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. doi:10.1007/s11102-013-0494-0
29. Siegel JA, Thomas SR, Stubbs JB et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40(2):37S–61S
30. Pernicone PJ, Scheithauer BW, Sebo TJ et al (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812
31. Salehi F, Agur A, Scheithauer BW et al (2009) Ki-67 in pituitary neoplasms: a review–part I. Neurosurgery 65:429–437 discussion 437
32. Janssen MH, Ollers MC, van Stiphout RG et al (2012) PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys 82:871–876
33. van Elmpt W, Ollers M, Dingemans AM et al (2012) Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med 53:1514–1520
34. Haug AR, Auernhammer CJ, Wangler B et al (2010) 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51:1349–1356
35. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754–2762
36. Hanscheid H, Sweeney RA, Flentje M et al (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284–1288
37. Cremonesi M, Botta F, Di Dia A et al (2010) Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 54:37–51
38. Hindorf C, Chittenden S, Causer L et al (2007) Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 22:130–135
39. Kaltsas GA, Papadogias D, Makras P et al (2005) Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 12:683–699
40. Villard L, Romer A, Marincek N et al (2012) Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30:1100–1106